Moderna appointed Michael McDonnell to its Board as a Class II director and Audit Committee member, and shifted David Rubenstein to the Nominating and Corporate Governance Committee.
| IndividualMichael McDonnellDavid Rubenstein | RoleClass II Director; member, Audit CommitteeDirector; appointed to Nominating and Corporate Governance Committee | Type of ChangeAppointedCommittee reassignment | Effective DateJuly 8, 2026July 8, 2026 | ReasonBoard appointment upon recommendation of Nominating and Corporate Governance CommitteeSimultaneous with McDonnell's appointment to Audit Committee | Replacement InfoNot disclosedVacated Audit Committee seat by appointment of McDonnell | Background Details35+ years of financial leadership; CFO of Biogen (Aug 2020–Feb 2025); former CFO of IQVIA, Intelsat, MCG Capital, EchoStarNot disclosed | Board/Committee Role ChangesAppointed to Audit CommitteeAppointed to Nominating and Corporate Governance Committee; ceased Audit Committee membership |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.